PCC Rokita SA

WSE:PCR Stock Report

Market Cap: zł1.3b

PCC Rokita Valuation

Is PCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of PCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: PCR (PLN64) is trading below our estimate of future cash flow value (PLN138.64)

Significantly Below Future Cash Flow Value: PCR is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PCR?

Key metric: As PCR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PCR. This is calculated by dividing PCR's market cap by their current earnings.
What is PCR's PE Ratio?
PE Ratio24.4x
Earningszł53.06m
Market Capzł1.30b

Price to Earnings Ratio vs Peers

How does PCR's PE Ratio compare to its peers?

The above table shows the PE ratio for PCR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.1x
HUB Hub.Tech
7.8xn/azł146.8m
SKA Fabryka Farb i Lakierów Sniezka
14.2xn/azł1.1b
SEL Selena FM
9.1xn/azł1.1b
BRS Boryszew
33.2xn/azł1.1b
PCR PCC Rokita
24.4x20.32%zł1.3b

Price-To-Earnings vs Peers: PCR is expensive based on its Price-To-Earnings Ratio (24.4x) compared to the peer average (16.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does PCR's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
PCR 24.4xIndustry Avg. 19.0xNo. of Companies11PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PCR is expensive based on its Price-To-Earnings Ratio (24.4x) compared to the European Chemicals industry average (18.9x).

Price to Earnings Ratio vs Fair Ratio

What is PCR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PCR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.4x
Fair PE Ratio11.8x

Price-To-Earnings vs Fair Ratio: PCR is expensive based on its Price-To-Earnings Ratio (24.4x) compared to the estimated Fair Price-To-Earnings Ratio (11.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PCR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł64.00
zł82.41
+28.76%
3.28%zł85.11zł79.70n/a2
Jul ’27zł64.00
zł82.41
+28.76%
3.28%zł85.11zł79.70n/a2
Jun ’27zł68.60
zł82.41
+20.12%
3.28%zł85.11zł79.70n/a2
May ’27zł70.40
zł81.79
+16.17%
2.55%zł83.87zł79.70n/a2
Apr ’27zł67.00
zł81.80
+22.09%
2.57%zł83.90zł79.70n/a2
Mar ’27zł69.20
zł85.65
+23.77%
2.04%zł87.40zł83.90n/a2
Feb ’27zł72.50
zł85.65
+18.14%
2.04%zł87.40zł83.90n/a2
Jan ’27zł61.30
zł85.64
+39.70%
2.06%zł87.40zł83.87n/a2
Dec ’26zł66.90
zł85.64
+28.00%
2.06%zł87.40zł83.87n/a2
Nov ’26zł68.30
zł85.64
+25.38%
2.06%zł87.40zł83.87n/a2
Oct ’26zł67.00
zł85.65
+27.84%
2.04%zł87.40zł83.90n/a2
Sep ’26zł69.20
zł85.65
+23.77%
2.04%zł87.40zł83.90n/a2
Aug ’26zł69.70
zł83.09
+19.21%
5.19%zł87.40zł78.78n/a2
Jul ’26zł66.20
zł83.09
+25.51%
5.19%zł87.40zł78.78zł64.002
Jun ’26zł72.00
zł88.73
+23.23%
9.82%zł100.00zł78.78zł68.603
May ’26zł78.30
zł88.73
+13.32%
9.82%zł100.00zł78.78zł70.403
Apr ’26zł74.10
zł88.73
+19.74%
9.82%zł100.00zł78.78zł67.003
Mar ’26zł75.90
zł88.73
+16.91%
9.81%zł100.00zł78.80zł69.203
Feb ’26zł73.60
zł89.99
+22.27%
8.16%zł100.00zł82.57zł72.503
Jan ’26zł69.00
zł89.99
+30.42%
8.16%zł100.00zł82.57zł61.303
Dec ’25zł71.30
zł89.99
+26.21%
8.16%zł100.00zł82.57zł66.903
Nov ’25zł80.00
zł93.32
+16.65%
12.81%zł110.00zł82.57zł68.303
Oct ’25zł80.80
zł97.79
+21.03%
11.66%zł110.00zł82.57zł67.003
Sep ’25zł85.90
zł97.79
+13.84%
11.66%zł110.00zł82.57zł69.203
Aug ’25zł90.00
zł97.80
+8.67%
11.64%zł110.00zł82.60zł69.703
Jul ’25zł91.50
zł100.40
+9.73%
0.40%zł100.80zł100.00zł66.202
zł82.41
Fair Value
22.3% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 08:04
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PCC Rokita SA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Henning EsskuchenErste Group Bank AG
Jakub SzkopekErste Group Bank AG
Adam MilewiczPKO BP Securities